Health
Experimental Drug ANB033 Shields Celiac Patients From Gluten Damage in Early Trial
First Tracks Biotherapeutics' ANB033, an investigational CD122 antagonist, significantly protected celiac patients against gluten-induced intestinal damage and symptoms…